We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+7.72%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$247M
AUM Growth
+$69.9M
Cap. Flow
+$48.7M
Cap. Flow %
19.75%
Top 10 Hldgs %
43.11%
Holding
96
New
14
Increased
43
Reduced
12
Closed
25

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$6.72M
2
APEN
Apollo Endosurgery, Inc.
APEN
+$6.46M
3
IMGN
Immunogen Inc
IMGN
+$5.37M
4
BLU
BELLUS Health Inc.
BLU
+$4.88M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.23M

Top Sells

Rank Stock Value
1
FULC icon
Fulcrum Therapeutics
FULC
+$5.24M
2
NXTC icon
NextCure
NXTC
+$3.68M
3
ARVN icon
Arvinas
ARVN
+$3.06M
4
INSM icon
Insmed
INSM
+$2.11M
5
ERAS icon
Erasca
ERAS
+$1.98M

Sector Composition

Rank Sector Weight
1 Healthcare 84.66%
2 Miscellaneous 9.6%
3 Financials 5.02%
4 Industrials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$22.4M 9.07%
+200,000
New +$24.1M
IMGN
2
DELISTED
Immunogen Inc
IMGN
$11.2M 4.55%
1,514,411
+864,492
+133% +$5.37M
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$11.1M 4.49%
80,348
+18,451
+30% +$2.35M
ITCI
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$10.2M 4.14%
195,000
+93,110
+91% +$3.91M
MRUS
5
DELISTED
Merus
MRUS
$10.2M 4.13%
320,174
-25,790
-7% -$729K
VCYT icon
6
Veracyte
VCYT
$3.48B
$9.12M 3.7%
221,362
+41,814
+23% +$1.85M
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.91M 3.61%
60,757
+14,816
+32% +$2.3M
BLU
8
DELISTED
BELLUS Health Inc.
BLU
$8.86M 3.59%
1,100,000
+735,000
+201% +$4.88M
COGT icon
9
Cogent Biosciences
COGT
$6.02B
$7.3M 2.96%
850,935
+173,035
+26% +$1.5M
LKFT
10
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$7.11M 2.88%
+128,901
New +$6.72M
CERS icon
11
Cerus
CERS
$534M
$7.1M 2.88%
1,042,722
+423,353
+68% +$2.85M
HZNP
12
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.65M 2.69%
61,700
+9,231
+18% +$1.01M
ITOS
13
DELISTED
iTeos Therapeutics
ITOS
$6.43M 2.6%
138,006
+21,075
+18% +$702K
APEN
14
DELISTED
Apollo Endosurgery, Inc.
APEN
$6.24M 2.53%
+739,604
New +$6.46M
RACB
15
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$5.42M 2.19%
556,890
+83,494
+18% +$821K
IMTX icon
16
Immatics
IMTX
$1.44B
$5.26M 2.13%
391,155
-46,711
-11% -$584K
LHDX
17
DELISTED
Lucira Health, Inc. Common Stock
LHDX
$4.43M 1.8%
515,000
+294,242
+133% +$1.87M
SRRA
18
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.17M 1.69%
192,045
+28,559
+17% +$629K
ACRS icon
19
Aclaris Therapeutics
ACRS
$885M
$4.16M 1.69%
286,226
+112,899
+65% +$1.71M
AMYT
20
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$3.78M 1.53%
350,213
-166,008
-32% -$1.79M
CTIC
21
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$3.68M 1.49%
+1,483,829
New +$3.63M
CYPH
22
Cypherpunk Technologies Inc
CYPH
$184M
$3.28M 1.33%
101,366
+39,366
+63% +$1.09M
KRYS icon
23
Krystal Biotech
KRYS
$10.4B
$3.27M 1.32%
+46,670
New +$2.72M
MORF
24
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$3.19M 1.29%
67,440
+9,736
+17% +$522K
CRNX icon
25
Crinetics Pharmaceuticals
CRNX
$9B
$3.18M 1.29%
111,860
+62,478
+127% +$1.54M
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Silverarc Capital Management held 96 positions worth $247M, up 40% from $177M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Silverarc Capital Management deployed $48.7M of net new capital in Q4 2021, opening 14 new positions and adding to 43 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 128,901 shares worth $7.11M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was NextCure, an estimated $3.68M trimmed.

  • Silverarc Capital Management's largest Q4 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 128,901 shares worth $7.11M.
  • Silverarc Capital Management added most to Immunogen Inc in Q4 2021, an estimated $5.37M increase.
  • Silverarc Capital Management's biggest Q4 2021 reduction was NextCure, cutting an estimated $3.68M.
  • Silverarc Capital Management fully exited Fulcrum Therapeutics in Q4 2021, selling an estimated $5.24M.
  • Silverarc Capital Management's ten largest holdings make up 43% of its $247M portfolio in Q4 2021.
  • Silverarc Capital Management opened 14 new positions and closed 25 in Q4 2021.
  • Silverarc Capital Management's portfolio value rose 40% quarter-over-quarter to $247M.

Based on Silverarc Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.